ENTA is currently developing the following drugs: Rosuvastatin, Midazolam, Caffeine, Edp-323, Carbamazepine, Itraconazole, Fluconazole, Quinidine, Edp-323, Moxifloxacin, Zelicapavir (Therapeutic Dose), Zelicapavir (Supratherapeutic Dose). These drug candidates are in various stages of clinical development as the company works toward FDA approval.